150 related articles for article (PubMed ID: 38117830)
1. CNP blocks mitochondrial depolarization and inhibits SARS-CoV-2 replication in vitro and in vivo.
Logue J; Melville VM; Ardanuy J; Frieman MB
PLoS Pathog; 2023 Dec; 19(12):e1011870. PubMed ID: 38117830
[TBL] [Abstract][Full Text] [Related]
2. CNP blocks mitochondrial depolarization and inhibits SARS-CoV-2 replication
Logue J; Melville VM; Ardanuy J; Frieman MB
bioRxiv; 2023 Dec; ():. PubMed ID: 37333151
[TBL] [Abstract][Full Text] [Related]
3. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
4. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M
mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634
[TBL] [Abstract][Full Text] [Related]
5. Amuvatinib Blocks SARS-CoV-2 Infection at the Entry Step of the Viral Life Cycle.
Huynh TTX; Pham TX; Lee GH; Lee JB; Lee SG; Tark D; Lim YS; Hwang SB
Microbiol Spectr; 2023 Jun; 11(3):e0510522. PubMed ID: 36995225
[TBL] [Abstract][Full Text] [Related]
6. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
7. Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches.
Bhowmik D; Nandi R; Jagadeesan R; Kumar N; Prakash A; Kumar D
Infect Genet Evol; 2020 Oct; 84():104451. PubMed ID: 32640381
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication.
Chu J; Xing C; Du Y; Duan T; Liu S; Zhang P; Cheng C; Henley J; Liu X; Qian C; Yin B; Wang HY; Wang RF
Nat Metab; 2021 Nov; 3(11):1466-1475. PubMed ID: 34580494
[TBL] [Abstract][Full Text] [Related]
9. Chemically modified antiviral peptides against SARS-CoV-2.
Quagliata M; Papini AM; Rovero P
J Pept Sci; 2024 Feb; 30(2):e3541. PubMed ID: 37699615
[TBL] [Abstract][Full Text] [Related]
10. Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19.
Chien M; Anderson TK; Jockusch S; Tao C; Li X; Kumar S; Russo JJ; Kirchdoerfer RN; Ju J
J Proteome Res; 2020 Nov; 19(11):4690-4697. PubMed ID: 32692185
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 Nucleocapsid Protein Is a Potential Therapeutic Target for Anticoronavirus Drug Discovery.
Royster A; Ren S; Ma Y; Pintado M; Kahng E; Rowan S; Mir S; Mir M
Microbiol Spectr; 2023 Jun; 11(3):e0118623. PubMed ID: 37199631
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
Datta PK; Liu F; Fischer T; Rappaport J; Qin X
Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
[TBL] [Abstract][Full Text] [Related]
13. An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension.
Fuchs E; Rudnik-Jansen I; Dinesen A; Selnihhin D; Mandrup OA; Thiam K; Kjems J; Pedersen FS; Howard KA
Acta Biomater; 2022 Nov; 153():411-418. PubMed ID: 36162760
[TBL] [Abstract][Full Text] [Related]
14. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome.
van de Veerdonk FL; Netea MG; van Deuren M; van der Meer JW; de Mast Q; Brüggemann RJ; van der Hoeven H
Elife; 2020 Apr; 9():. PubMed ID: 32338605
[TBL] [Abstract][Full Text] [Related]
15. Restriction of SARS-CoV-2 replication by receptor transporter protein 4 (RTP4).
Kaur R; Tada T; Landau NR
mBio; 2023 Aug; 14(4):e0109023. PubMed ID: 37382452
[TBL] [Abstract][Full Text] [Related]
16. Honokiol Inhibits SARS-CoV-2 Replication in Cell Culture at a Post-Entry Step.
Salgado-Benvindo C; Leijs AA; Thaler M; Tas A; Arbiser JL; Snijder EJ; van Hemert MJ
Microbiol Spectr; 2023 Jun; 11(3):e0327322. PubMed ID: 37212560
[TBL] [Abstract][Full Text] [Related]
17. COVID-19: inflammatory responses, structure-based drug design and potential therapeutics.
Tripathi N; Tripathi N; Goshisht MK
Mol Divers; 2022 Feb; 26(1):629-645. PubMed ID: 33400086
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic targeting of the ACE2 and NRP1 viral receptors limits SARS-CoV-2 infectivity.
Saiz ML; DeDiego ML; López-García D; Corte-Iglesias V; Baragaño Raneros A; Astola I; Asensi V; López-Larrea C; Suarez-Alvarez B
Clin Epigenetics; 2021 Oct; 13(1):187. PubMed ID: 34635175
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of HIV-1 particle assembly by 2',3'-cyclic-nucleotide 3'-phosphodiesterase.
Wilson SJ; Schoggins JW; Zang T; Kutluay SB; Jouvenet N; Alim MA; Bitzegeio J; Rice CM; Bieniasz PD
Cell Host Microbe; 2012 Oct; 12(4):585-97. PubMed ID: 23084924
[TBL] [Abstract][Full Text] [Related]
20. Proteomic analysis of SARS-CoV-2 particles unveils a key role of G3BP proteins in viral assembly.
Murigneux E; Softic L; Aubé C; Grandi C; Judith D; Bruce J; Le Gall M; Guillonneau F; Schmitt A; Parissi V; Berlioz-Torrent C; Meertens L; Hansen MMK; Gallois-Montbrun S
Nat Commun; 2024 Jan; 15(1):640. PubMed ID: 38245532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
